October 22, 2020
Biogen has submitted a marketing authorization application (MAA) in Europe for its Alzheimer’s drug aducanumab, the company said in its third-quarter financial update. The big biotech now awaits the acceptance of the MAA by European regulators, while gearing up for...read more